Immuron hails record monthly sales of Travelan

–News Direct–

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan. For August, the company registered Australian sales amounting to A$1.18 million, representing a staggering 7,984% increase compared to A$14,581 in August 2022. The monumental sales boost partially mirrors the clearance of a three-month backlog of orders, which had accumulated during a period awaiting Good Manufacturing Practice (GMP) clearance from the TGA.

Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers diarrhea,

Travelan is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers diarrhea. In Australia, Travelan is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers Diarrhea. In the U.S., Travelan is sold as a dietary supplement for digestive tract protection.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

View source version on

Immuron Ltd

comtex tracking


About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Scotland News journalist was involved in the writing and production of this article.